OJMIP  Vol.5 No.1 , February 2015
Nuclear Factor-Kappa B and Other Oxidative Stress Biomarkers in Serum of Autistic Children
Abstract: The aim of the present study was to investigate the status of oxidative stress in the serum of children affected with autism spectrum disorder. Twenty autistic children aged 3 to 12 years, were gender and age-matched with 20 typically developing children. Changes in the levels of the redox-sensing transcription factor nuclear factor-kappa B (NF-κB) was measured in serum of autistic children and controls. Other oxidative stress biomarkers such as malondialdehyde, reduced glutathione, total antioxidant capacity, catalase activity, and paraoxonase 1 activity were determined in serum as well. Significant increase was observed in serum NF-κB of autistic children compared to that in controls (by 138.6%). There was also marked increase in malondialdehyde level by 87.3% in autistic patients. Meanwhile, there were significant decreases in reduced glutathione (by 24%), catalase activity (by 40.8%), paraoxonase 1 activity (by 36.6%), and total antioxidant capacity (by 36.5%) compared to the control group. These data clearly demonstrate increased oxidative stress in serum of autistic children and suggest that the NF-κB signaling pathway is activated in autism, possibly due to increased oxidative burden.
Cite this paper: E. Abdel-Salam, O. , Youness, E. , Mohammed, N. and Elhamed, W. (2015) Nuclear Factor-Kappa B and Other Oxidative Stress Biomarkers in Serum of Autistic Children. Open Journal of Molecular and Integrative Physiology, 5, 18-27. doi: 10.4236/ojmip.2015.51002.

[1]   American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. 4th Edition, American Psychiatric Association, Washington DC.

[2]   Baird, G., Cass, H. and Slonims, V. (2003) Diagnosis of Autism. BMJ, 327, 488-493.

[3]   Fombonne, E., Zakarian, R., Bennett, A., Meng, L. and McLean-Heywood, D. (2006) Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links with Immunizations. Pediatrics, 118, e139-e150.

[4]   Napoli, E., Wong, S. and Giulivi, C. (2013) Evidence of Reactive Oxygen Species-Mediated Damage to Mitochondrial DNA in Children with Typical Autism. Molecular Autism, 4, 2.

[5]   Gargus, J.J. and Imtiaz, F. (2008) Mitochondrial Energy-Deficient Endophenotype in Autism. American Journal of Biochemistry and Biotechnology. Special Issue on Autism Spectrum Disorders, 4, 198-207.

[6]   Cohly, H.H. and Panja, A. (2005) Immunological Findings in Autism. International Review of Neurobiology, 71, 317-341.

[7]   Theoharides, T.C., Asadi, S. and Patel, A.B. (2013) Focal Brain Inflammation and Autism. Journal of Neuroinflammation, 10, 46.

[8]   De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Ercument Cicek, A., Kou, Y., Liu, L. et al. (2014) Synaptic, Transcriptional and Chromatin Genes Disrupted in Autism. Nature, 515, 209-215.

[9]   Edelson, S.B. and Cantor, D.S. (2000) The Neurotoxic Etiology of the Autistic Spectrum Disorder: A Replicative Study. Toxicology and Industrial Health, 16, 239-247.

[10]   Vojdani, A., Campbell, A.W., Anyanwu, E., Kashanian, A., Bock, K. and Vojdani, E. (2002) Antibodies to Neuron-Specific Antigens in Children with Autism: Possible Cross Reaction with Encephalitogenic Proteins from Milk, Chlamydia Pneumoniae and Stretoccoccus Group A. Journal of Neuroimmunology, 129, 168-177.

[11]   Vojdani, A., Mumper, E., Granpeesheh, D., Mielke, L., Traver, D., Bock, K., Hirani, K., Neubrander, J., Woeller, K.N., O’Hara, N., Usman, A., Schneider, C., Hebroni, F., Berookhim, J. and McCandless, J. (2008) Low Natural Killer Cell Cytotoxic Activity in Autism: The Role of Glutathione, IL-2 and IL-15. Journal of Neuroimmunology, 205, 148-154.

[12]   Halliwell, B. (2001) Role of Free Radicals in the Neurodegenerative Diseases. Drugs & Aging, 18, 685-716.

[13]   Hirsch, E.C. and Hunot, S. (2009) Neuroin-flammation in Parkinson’s Disease: A Target for Neuroprotection? The Lancet Neurology, 8, 382-397.

[14]   Dasuri, K., Zhang, L. and Keller, J.N. (2013) Oxidative Stress, Neurodegeneration, and the Balance of Protein Degradation and Protein Synthesis. Free Radical Biology and Medicine, 62, 170-185.

[15]   Yao, J.K. and Reddy, R. (2011) Oxidative Stress in Schizophrenia: Pathogenetic and Therapeutic Implications. Antioxidants & Redox Signaling, 15, 1999-2002.

[16]   Haider, L., Fischer, M.T., Frischer, J.M., Bauer, J., Hoftberger, R., Botond, G., Esterbauer, H., Binder, C.J., Witztum, J.L. and Lassmann, H. (2011) Oxidative Damage in Multiple Sclerosis Lesions. Brain, 134, 1914-1924.

[17]   Sies, H. (1997) Oxidative Stress: Oxidants and Antioxidants. Experimental Physiology, 82, 291-295.

[18]   Bains, J.S. and Shaw, C.A. (1997) Neurodegenerative Disorders in Humans: The Role of Glutathione in Oxidative Stress-Mediated Neuronal Death. Brain Research Reviews, 25, 335-358.

[19]   Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P. and Marsden, C.D. (1994) Alterations in Glutathione Levels in Parkinson’s Disease and Other Neurodegenerative Disorders Affecting Basal Ganglia. Annals of Neurology, 36, 348-355.

[20]   Dickinson, D.A. and Forman, H.J. (2002) Cellular Glutathione and Thiols Metabolism. Biochemical Pharmacology, 64, 1019-1026.

[21]   Li, N. and Karin, M. (1999) Is NF-κB the Sensor of Oxidative Stress? The FASEB Journal, 13, 1137-1143.

[22]   Sen, R. and Baltimore, D. (1986) Indicibility of κ Immunoglobulin Enhancer-Binding Protein NF-κB by a Posttranslational Mechanism. Cell, 47, 921-928.

[23]   Christman, J.W., Blackwell, T.S. and Juurlink, B.H.J. (2000) Redox Regulation of Nuclear Factor Kappa B: Therapeutic Potential for Attenuating Inflammatory Responses. Brain Pathology, 10, 153-162.

[24]   Haddad, J.J. (2002) Redox Regulation of Pro-Inflammatory Cytokines and IκB-α/NF-κB Nuclear Translocation and Activation. Biochemical and Biophysical Research Communications, 296, 847-856.

[25]   Celec, P. (2004) Nuclear Factor Kappa B—Molecular Biomedicine: The Next Generation. Biomedicine & Pharmacotherapy, 58, 365-371.

[26]   Gutteridge, J.M. (1995) Lipid Peroxidation and Antioxidants as Biomarkers of Tissue Damage. Clinical Chemistry, 41, 1819-1828.

[27]   Furlong, C.E. (2008) Paraoxonases: An Historical Perspective. In: Mackness, B., Mackness, M., Aviram, M. and Paragh, G., Eds., The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism, Springer, Dordrecht, 3-31.

[28]   Menini, T. and Gugliucci, A. (2014) Paraoxonase 1 in Neurological Disorders. Redox Report, 19, 49-58.

[29]   Ruiz-Larrea, M.B., Leal, A.M., Liza, M., Lacort, M. and de Groot, H. (1994) Antioxidant Effects of Estradiol and 2-Hydroxyestradiol on Iron-Induced Lipid Peroxidation of Rat Liver Microsomes. Steroids, 59, 383-388.

[30]   Beutler, M., Duron, O. and Kelly, B.M. (1963) Improved Method for the Determination of Blood Glutathione. Journal of Laboratory and Clinical Medicine, 61, 882-888.

[31]   Koracevic, D., Koracevic, G. and Djordjevic, V. (2001) Method for the Measurement of Antioxidant Activity in Human Fluids. Journal of Clinical Pathology, 54, 356-361.

[32]   Aebi, H. (1984) Catalase in Vitro. Methods in Enzymology, 105, 121-126.

[33]   Higashino, K., Takahashi, Y. and Yamamura, Y. (1972) Release of Phenyl Acetate Esterase from Liver Microsomes by Carbon Tetrachloride. Clinica Chimica Acta, 41, 313-320.

[34]   Watson, A.D., Berliner, J.A., Hama, S.Y., La Du, B.N., Faull, K.F., Fogelman, A.M. and Navab, M. (1995) Protective Effect of High Density Lipoprotein Associated Paraoxonase. Inhibition of the Biological Activity of Minimally Oxidized Low Density Lipoprotein. The Journal of Clinical Investigation, 96, 2882-2891.

[35]   Van den Berg, R., Haenen, G.R.M.M., Van den Berg, H. and Bast, A. (2001) Transcription Factor NF-κB as a Potential Biomarker for Oxidative Stress. British Journal of Nutrition, 86, 121-127.

[36]   Naik, U.S., Gangadharan, C., Abbagani, K., Nagalla, B., Dasari, N. and Manna, S.K. (2011) A Study of Nuclear Transcription Factor-Kappa B in Childhood Autism. PLoS ONE, 6, e19488.

[37]   Young, A.M., Campbell, E., Lynch, S., Suckling, J. and Powis, S.J. (2011) Aberrant NF-KappaB Expression in Autism Spectrum Condition: A Mechanism for Neuroinflammation. Frontiers in Psychiatry, 2, 27.

[38]   Malik, M., Tauqeer, Z., Sheikh, A.M., Wen, G., Nagori, A., Yang, K., Brown, W.T. and Li, X. (2011) NF-κB Signaling in the Brain of Autistic Subjects. Mediators of Inflammation, 2011, Article ID: 785265.

[39]   Halliwell, B. and Gutteridge, J.M.C. (1989) Free Radicals in Biology and Medicine. 2nd Edition, Clarendon Press, Oxford, 22-85.

[40]   Sies, H. (1991) Role of Reactive Oxygen Species in Biological Processes. Klinische Wochenschrift, 69, 965-968.

[41]   Halliwell, B. and Whiteman, M. (2004) Measuring Reactive Species and Oxidative Damage in Vivo and in Cell Culture: How Should You Do It and What Do the Results Mean? British Journal of Pharmacology, 142, 231-255.

[42]   Halliwell, B. and Cross, C.E. (1994) Oxygen-Derived Species: Their Relation to Human Disease and Environmental Stress. Environmental Health Perspectives, 102, 5-12.

[43]   Halliwell, B. (2007) Biochemistry of Oxidative Stress. Biochemical Society Transactions, 35, 1147-1150.

[44]   Martin, H.L. and Teismann, P. (2009) Glutathione—A Review on Its Role and Significance in Parkinson’s Disease. The FASEB Journal, 23, 3263-3272.

[45]   Aoyama, K., Watabe, M. and Nakaki, T. (2008) Regulation of Neuronal Glutathione Synthesis. Journal of Pharmacological Sciences, 108, 227-238.

[46]   González-Fraguela, M.E., Hung, M.-L.D., Vera, H., Maragoto, C., Noris, E., Blanco, L., Galvizu, R. and Robinson, M. (2013) Oxidative Stress Markers in Children with Autism Spectrum Disorders. British Journal of Medicine and Medical Research, 3, 307-317.

[47]   Pecorelli, A., Leoncini, S., De Felice, C., Signorini, C., Cerrone, C., Valacchi, G., Ciccoli, L. and Hayek, J. (2013) Non-Protein-Bound Iron and 4-Hydroxynonenal Protein Adducts in Classic Autism. Brain & Development, 35, 146-154.

[48]   James, S.J., Rose, S., Melnyk, S., Jernigan, S., Blossom, S., Pavliv, O. and Gaylor, D.W. (2009) Cellular and Mitochondrial Glutathione Redox Imbalance in Lymphoblastoid Cells Derived from Children with Autism. The FASEB Joural, 23, 2374-2383.

[49]   Chauhan, A., Audhya, T. and Chauhan, V. (2012) Brain Region-Specific Glutathione Redox Imbalance in Autism. Neurochemical Researchs, 37, 1681-1689.

[50]   Gu, F., Chauhan, V. and Chauhan, A. (2013) Impaired Synthesis and Antioxidant Defense of Glutathione in the Cerebellum of Autistic Subjects: Alterations in the Activities and Protein Expression of Glutathione-Related Enzymes. Free Radical Biology and Medicine, 65, 488-496.

[51]   Hauser, R.A., Lyons, K.E., McClain, T., Carter, S. and Perlmutter, D. (2009) Randomized, Double-Blind, Pilot Evaluation of Intravenous Glutathione in Parkinson’s Disease. Movement Disorders, 24, 979-983.

[52]   Do, K.Q., Bovet, P. and Cuenod, M. (2004) Schizophrenia: Glutathione Deficit as a New Vulnerability Factor for Disconnectivity Syndrome. Schweizer Archiv für Neurologie, Neurochirurgie und Psychiatrie, 155, 375-385.

[53]   Prior, R.L. and Cao, G. (1999) In Vivo Total Antioxidant Capacity: Comparison of Different Analytical Methods. Free Radical Biology and Medicine, 27, 1173-1181.

[54]   Vassalle, C., Masini, S., Carpeggiani, C., L’Abbate, A., Boni, C. and Zucchelli, G.C. (2004) In Vivo Total Antioxidant Capacity: Comparison of Two Different Analytical Methods. Clinical Chemistry and Laboratory Medicine, 42, 84-89.

[55]   Ziyatdinova, G.K., Budnikov, H.C., Pogoreltzev, V.I. and Ganeev, T.S. (2006) The Application of Coulometry for Total Antioxidant Capacity Determination of Human Blood. Talanta, 68, 800-805.

[56]   Suresh, D.R., Annam, V., Pratibha, K. and Prasad, M.B.V. (2009) Total Antioxidant Capacity—A Novel Early Bio-Chemical Marker of Oxidative Stress in HIV Infected Individuals. Journal of Biomedical Science, 16, 61.

[57]   Papageorgiou, M., Stiakaki, E., Dimitriou, H., Malliaraki, N., Notas, G., Castanas, E. and Kalmanti, M. (2005) Cancer Chemotherapy Reduces Plasma Total Antioxidant Capacity in Children with Malignancies. Leukemia Research, 29, 11-16.

[58]   Abdel-Salam, O.M.E., Youness, E.R. and Hafez, H.F. (2011) The Antioxidant Status of the Plasma in Patients with Breast Cancer Undergoing Chemotherapy. Open Journal of Molecular and Integrative Physiology, 1, 29-35.

[59]   Primo-Parmo, S.L., Sorenson, R.C., Teiber, J. and La Du, B.N. (1996) The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is One Member of a Multigene Family. Genomics, 33, 498-507.

[60]   Mackness, B., Quarck, R., Verreth, W., Mackness, M. and Holvoet, P. (2006) Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1545-1550.

[61]   Jamroz-Wisniewska, A., Beltowski, J., Stelmasiak, Z. and Bartosik-Psujek, H. (2009) Paraoxonase 1 Activity in Different Types of Multiple Sclerosis. Multiple Sclerosis Journal, 15, 399-402.

[62]   Kotan, V.O., Sarandol, E., Kirhan, E., Ozkaya, G. and Kirli, S. (2011) Effects of Long-Term Antidepressant Treatment on Oxidative Status in Major Depressive Disorder: A 24-Week Follow-Up Study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 1284-1290.

[63]   Zengi, O., Karakas, A., Ergun, U., Senes, M., Inan, L. and Yucel, D. (2011) Urinary 8-Hydroxy-2’-Deoxyguanosine Level and Plasma Paraoxonase 1 Activity with Alzheimer’s Disease. Clinical Chemistry and Laboratory Medicine, 50, 529-534.

[64]   Wehr, H., Bednarska-Makaruk, M., Graban, A., Lipczyńska-Lojkowska, W., Rodo, M., Bochyńska, A. and Ryglewicz, D. (2009) Paraoxonase Activity and Dementia. Journal of the Neurological Sciences, 283, 107-108.

[65]   Gaita, L., Manzi, B., Sacco, R., Lintas, C., Altieri, L., Lombardi, F., Pawlowski, T.L., Redman, M., Craig, D.W., Huentelman, M.J., Ober-Reynolds, S., Brautigam, S., Melmed, R., Smith, C.J., Marsillach, J., Camps, J., Curatolo, P. and Persico, A.M. (2010) Decreased Serum Arylesterase Activity in Autism Spectrum Disorders. Psychiatry Research, 180, 105-113.

[66]   Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton, R.S. and La Du, B. (1999) Human Serum Paraoxonase (PON 1) Is Inactivated by Oxidized Low Density Lipoprotein and Preserved by Antioxidants. Free Radical Biology and Medicine, 26, 892-904.

[67]   Seres, I., Fulop, T., Paragh, G. and Khalil, A. (2008) Age-Related Alterations in PON1. In: Mackness, B., Mackness, M., Aviram, M. and Paragh, G., Eds., The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism, Springer, Dordrecht, 199-206.